BFB759

BIOLOGICAL4 trials

Sponsors

Bluefin Biomedicine Inc., Bluefin Biomedicine, Inc.

Conditions

Atopic Dermatitis (AD)Atopic dermatitisHidradenitis SuppurativaHidradenitis Suppurativa (HS)

Phase 2

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Active, not recruitingNCT07105488

Bluefin Biomedicine, Inc.Atopic Dermatitis (AD)

Start: 2025-07-15End: 2027-03-31Target: 225Updated: 2026-07-30

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Atopic Dermatitis (COMPASS 2-AD)

RecruitingCTIS2025-521624-30-00

Bluefin Biomedicine Inc.Atopic dermatitis

Start: 2026-01-08Target: 90Updated: 2025-12-05

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

RecruitingNCT07287644

Bluefin Biomedicine, Inc.Hidradenitis Suppurativa (HS)

Start: 2025-11-03End: 2027-08-01Target: 210Updated: 2026-05-29

A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)

Not yet recruitingCTIS2025-522440-41-00

Bluefin Biomedicine Inc.Hidradenitis Suppurativa

Target: 36Updated: 2026-04-01